The Prostate Cancer Charity comments on the decision by the
National Institute for Health and Clinical Excellence (NICE) not to
recommend the newly licensed chemotherapy drug cabazitaxel as a
treatment for men with advanced prostate cancer, which has been
shown to significantly extend the lives of men in the advanced
stages of the disease.